Praxbind Injection

Idarucizumab
50mg/ml
Boehringer Ingelheim International GmbH
Pack size 50ml Glass Vial x 2
Dispensing mode POM
Source GERMANY
AgentGULF DRUG EST.
Retail Price 13934.50 AED

Indications

Praxbind Injection is used for: Dabigatran Reversal

Adult Dose

Dabigatran Reversal Humanized monoclonal antibody fragment (Fab) indicated in patients treated with dabigatran when reversal of the anticoagulant effects are needed for emergency surgery or urgent procedures, or in the event of life-threatening or uncontrolled bleeding 5 g IV, provided as 2 separate vials each containing 2.5 g/50 mL

Child Dose

Renal Dose

Renal impairment: Renal impairment did not impact the reversal effect of idarucizumab; no dosage adjustment required

Administration

IV Preparation Ensure aseptic handling when preparing Inspect visually for particulates and discoloration before infusion Once solution has been removed from the vial, administration should begin promptly; solution in vials may be stored at room temperature (25°C [77°F]), but must be used within 6 hr (also see storage) Do not mix with other medications IV Administration Infuse 5-g dose IV as 2 consecutive 2.5-g infusions or give as a bolus injections by injecting both 2.5-g vials consecutively one after another via syringe A preexisting IV line may be used for administration; flush with sterile 0.9% NaCl solution prior to infusion No other infusion should be administered in parallel via the same IV access Can be used in conjunction with standard supportive measures, which should be considered as medically appropriate

Contra Indications

Precautions

Patients treated with dabigatran have underlying disease states that predispose them to thromboembolic events; reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease; to reduce this risk, resume anticoagulant therapy as soon as medically appropriate There is insufficient clinical experience to evaluate risk of hypersensitivity to idarucizumab; discontinue if a serious hypersensitivity reaction occurs Caution with hereditary fructose intolerance; the recommended dose of idarucizumab contains 4 g sorbitol as an excipient; when prescribing to patients with hereditary fructose intolerance, consider the combined daily metabolic load of sorbitol/fructose from all sources; administration of sorbitol in these patients is known to cause serious adverse reactions, including fatal reactions including hypoglycemia, hypophosphatemia, metabolic acidosis, increase in uric acid, and acute liver failure with breakdown of excretory and synthetic function

Pregnancy-Lactation

Pregnancy There are no adequate and well-controlled studies of idarucizumab in pregnant women to inform on associated risks Animal reproductive and development studies have not been conducted; it is also not known whether idarucizumab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity Has not been studied for use during labor and delivery Lactation Unknown if distributed in human breast milk Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Interactions

Adverse Effects

Side effects of Idarucizumab : 1-10% Hypokalemia (7%) Delirium (7%) Constipation (7%) Pyrexia (6%) Pneumonia (6%) Headache (5%) Frequency Not Defined Thromboembolic events Hypersensitivity

Mechanism of Action

Specific reversal agent for dabigatran It is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran and its acylglucuronide metabolites with higher affinity than the binding affinity of dabigatran to thrombin, and thereby neutralizes dabigatran and its metabolites anticoagulant effect

Note

Praxbind 50mg/ml Injection manufactured by Boehringer Ingelheim International GmbH. Its generic name is Idarucizumab. Praxbind is availble in United Arab Emirates. Farmaco UAE drug index information on Praxbind Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Idarucizumab :